Nextage Therapeutics Current Valuation vs. Total Debt

MCTC Stock  ILA 71.90  2.20  2.97%   
Based on Nextage Therapeutics' profitability indicators, Nextage Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in May. Profitability indicators assess Nextage Therapeutics' ability to earn profits and add value for shareholders.
For Nextage Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nextage Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nextage Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nextage Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nextage Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between Nextage Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nextage Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nextage Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Nextage Therapeutics Total Debt vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Nextage Therapeutics's current stock value. Our valuation model uses many indicators to compare Nextage Therapeutics value to that of its competitors to determine the firm's financial worth.
Nextage Therapeutics is currently under evaluation in current valuation category among related companies. It is currently under evaluation in total debt category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nextage Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nextage Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nextage Therapeutics' earnings, one of the primary drivers of an investment's value.

Nextage Current Valuation vs. Competition

Nextage Therapeutics is currently under evaluation in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 25.05 Million. Nextage Therapeutics adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.

Nextage Total Debt vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Nextage Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
null
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Nextage Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
null
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Nextage Total Debt vs Competition

Nextage Therapeutics is currently under evaluation in total debt category among related companies. Total debt of Health Care industry is now estimated at about 5.7 Million. Nextage Therapeutics adds roughly 0.0 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Revenue  Workforce  Capitalization  Valuation

Nextage Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Nextage Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nextage Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Nextage Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Nextage Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.

Nextage Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Nextage Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nextage Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nextage Therapeutics' important profitability drivers and their relationship over time.

Use Nextage Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nextage Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nextage Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Nextage Therapeutics Pair Trading

Nextage Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Nextage Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nextage Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nextage Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nextage Therapeutics to buy it.
The correlation of Nextage Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nextage Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nextage Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nextage Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Nextage Therapeutics position

In addition to having Nextage Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Junk Bonds Funds Thematic Idea Now

Junk Bonds Funds
Junk Bonds Funds Theme
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Nextage Stock analysis

When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Stocks Directory
Find actively traded stocks across global markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bonds Directory
Find actively traded corporate debentures issued by US companies
To fully project Nextage Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nextage Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nextage Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Nextage Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Nextage Therapeutics investors may work on each financial statement separately, they are all related. The changes in Nextage Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nextage Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.